Norfloxacin
| Clinical data | |
|---|---|
| Trade names | Noroxin, Chibroxin, Trizolin, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a687006 |
| Routes of administration | Oral, ophthalmic |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 30 to 40% |
| Protein binding | 10 to 15% |
| Metabolism | Hepatic |
| Elimination half-life | 3 to 4 hours |
| Excretion | Renal and fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.067.810 |
| Chemical and physical data | |
| Formula | C16H18FN3O3 |
| Molar mass | 319.336 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 220 to 221 °C (428 to 430 °F) |
| |
| |
| (verify) | |
Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.
Norfloxacin is associated with a number of rare serious adverse reactions as well as spontaneous tendon ruptures and irreversible peripheral neuropathy. Tendon problems may manifest long after therapy had been completed and in severe cases may result in lifelong disabilities.
It was patented in 1977 and approved for medical use in 1983.